Medicines for Dementia due to Alzheimer's Disease and Parkinson's Disease

Donepezil, rivastigmine and galantamine are reimbursed for the treatment of mild to moderate dementia due to Alzheimer's Disease (AD). Rivastigmine is also reimbursed for the treatment of mild to moderate dementia due to Parkinson's Disease (PD). For the treatment of moderate to severe dementia due to AD, memantine is reimbursed.
The clinical benefit of these drugs is unclear. This HTA aims to evaluate the available clinical and economic evidence associated with these treatments in patients with dementia due to AD or PD in Switzerland.

Last modification 05.11.2021

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/medikamentebeialzheimerdemenz.html